Abstract
Rationale: Recently, the new cytokine interleukin (IL) 37 has been described as a negative regulator of the innate immune system. It reduces activation of DCs and the production of pro-inflammatory mediators in TLR stimulated murine and human macrophage, monocyte and epithelial cell lines. Results from the CLARA study gave the first hint towards an implication of IL-37 in asthma pathogenesis. However, until yet it is unknown, whether IL-37 plays a role in asthma pathogenesis by providing anti-inflammatory effects on an adaptive immune response and through which receptor it exerts such effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
